According to Eastell et al. [180], bisphosphonates and most other anti-resorptive drugs (e.g., denosumab, selective estrogen receptor modulators, and odanacatib) have similar efficacy in reducing fracture risk in individuals with and without T2DM. Here, ESR1 is linked to type 2 diabetes mellitus.